Literature DB >> 32634289

Post-transplant survey to assess patient experiences with donor-derived HCV infection.

Katya Prakash1, Claudia Ramirez-Sanchez1, Sydney I Ramirez1, Cathy Logan1, Nancy Law1, Kristin Mekeel2, Victor Pretorius2, Saima Aslam1.   

Abstract

BACKGROUND: Despite increased utilization of hepatitis C virus-infected (HCV+) organs for transplantation into HCV-uninfected recipients, there is lack of standardization in HCV-related patient education/consent and limited data on financial and social impact on patients.
METHODS: We conducted a survey on patients with donor-derived HCV infection at our center transplanted between 4/1/2017 and 11/1/2019 to assess: why patients chose to accept HCV+ organ(s), the adequacy of their pre-transplant HCV education and informed consent process, financial issues related to copays after discharge, and social challenges they faced.
RESULTS: Among 49 patients surveyed, transplanted organs included heart (n = 19), lung (n = 9), kidney (n = 11), liver (n = 4), heart/kidney (n = 4), and liver/kidney (n = 2). Many recipients accepted an HCV-viremic (HCV-V) organ due to perceived reduction in waitlist time (n = 33) and/or trust in their physician's recommendation (n = 29). Almost all (n = 47) felt that pre-transplant education and consent was appropriate. Thirty patients had no copay for direct-acting antivirals (DAA) for HCV, including 21 with household income <$20 000; seven had copays of <$100 and one had a copay >$1000. Two patients reported feeling isolated due to HCV infection and eight reported higher than anticipated medication costs. Patients' biggest concern was potential HCV transmission to partners (n = 18) and family/friends (n = 15). Overall almost all (n = 47) patients reported a positive experience with HCV-V organ transplantation.
CONCLUSION: We demonstrate that real-world patient experiences surrounding HCV-V organ transplantation have been favorable. Almost all patients report comprehensive HCV-related pre-transplant consent and education. Additionally, medication costs and social isolation/exclusion were not barriers to the use of these organs.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  DAA cost; HCV organ transplant; consent; donor-derived HCV; education

Year:  2020        PMID: 32634289     DOI: 10.1111/tid.13402

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  3 in total

Review 1.  Kidney Transplantation From Hepatitis-C Viraemic Donors:Considerations for Practice in the United Kingdom.

Authors:  Daniel T Doherty; Varinder Athwal; Zia Moinuddin; Titus Augustine; Martin Prince; David van Dellen; Hussein A Khambalia
Journal:  Transpl Int       Date:  2022-05-03       Impact factor: 3.842

2.  Patients' Experiences With HIV-positive to HIV-positive Organ Transplantation.

Authors:  Sarah E Van Pilsum Rasmussen; Shanti Seaman; Morgan A Johnson; Karen Vanterpool; Diane M Brown; Aaron A R Tobian; Timothy Pruett; Varvara Kirchner; Faith E Fletcher; Burke Smith; Sonya Trinh; Dorry L Segev; Christine M Durand; Jeremy Sugarman
Journal:  Transplant Direct       Date:  2021-08-06

3.  Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections.

Authors:  Zoe A Stewart; Jeffrey Stern; Nicole M Ali; Harmit S Kalia; Karen Khalil; Srijana Jonchhe; Elaina P Weldon; Rebecca A Dieter; Tyler C Lewis; Nur Funches; Sudara Crosby; Monique Seow; Jonathan C Berger; Nabil N Dagher; Bruce E Gelb; Anthony C Watkins; Nader Moazami; Deane E Smith; Zachary N Kon; Stephanie H Chang; Alex Reyentovich; Luis F Angel; Robert A Montgomery; Bonnie E Lonze
Journal:  Transplant Direct       Date:  2021-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.